Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves

详细信息    查看全文

• 作者：John C. Morrill ; Richard C. Laughlin ; N ; adeva Lokugamage ; Jing Wu ; Roberta Pugh ; Pooja Kanani ; L. Garry Adams ; Shinji Makino ; C.J. Peters
• 关键词：Rift Valley fever ; RVF MP-12-NSm deletion vaccine ; arMP-12¦¤NSm21/384 ; Calves
• 刊名：Vaccine
• 出版年：2013
• 出版时间：9 October, 2013
• 年：2013
• 卷：31
• 期：43
• 页码：4988-4994
• 全文大小：749 K

文摘

The safety and immunogenicity of an authentic recombinant (ar) of the live, attenuated MP-12 Rift Valley fever (RVF) vaccine virus with a large deletion of the NSm gene in the pre-Gn region of the M RNA segment (arMP-12¦¤NSm21/384) was tested in 4-6 month old Bos taurus calves. Phase I of this study evaluated the neutralizing antibody response, measured by 80 % plaque reduction neutralization (PRNT₈₀), and clinical response of calves to doses of 1 ¡Á 10¹ through 1 ¡Á 10⁷ plaque forming units (PFU) administered subcutaneously (s.c.). Phase II evaluated the clinical and neutralizing antibody response of calves inoculated s.c. or intramuscularly (i.m.) with 1 ¡Á 10³, 1 ¡Á 10⁴ or 1 ¡Á 10⁵ PFU of arMP-12¦¤NSm21/384. No significant adverse clinical events were observed in the animals in these studies. Of all specimens tested, only one vaccine viral isolate was recovered and that virus retained the introduced deletion. In the Phase I study, there was no statistically significant difference in the PRNT₈₀ response between the dosage groups though the difference in IgG response between the 1 ¡Á 10¹ PFU group and the 1 ¡Á 10⁵ PFU group was statistically significant (p < 0.05). The PRNT₈₀ response of the respective dosage groups corresponded to dose of vaccine with the 1 ¡Á 10¹ PFU dose group showing the least response. The Phase II study also showed no statistically significant difference in PRNT₈₀ response between the dosage groups though the difference in RVFV-specific IgG values was significantly increased (p < 0.001) in animals inoculated i.m. with 1 ¡Á 10⁴ or 1 ¡Á 10⁵ PFU versus those inoculated s.c. with 1 ¡Á 10³ or 1 ¡Á 10⁵ PFU. Although the study groups were small, these data suggest that 1 ¡Á 10⁴ or 1 ¡Á 10⁵ PFU of arMP-12¦¤NSm21/384 administered i.m. to calves will consistently stimulate a presumably protective PRNT₈₀ response for at least 91 days post inoculation. Further studies of arMP-12¦¤NSm21/384 are warranted to explore its suitability as an efficacious livestock vaccine.